NEW YORK, June 12, 2026 /PRNewswire/ — Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, applauds today's decision from the U.S. Food and Drug Administration (FDA) to approve Tzield for use in individuals ages…

Read the full release →

News provided by PR Newswire.